Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition

NCT07332338 is registered in ClinicalTrials.gov with StemCyte, Inc. as lead sponsor.

NCT NCT07332338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07332338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion for Patients With Post-COVID Condition
Lead sponsor
StemCyte, Inc.
Phase
Expanded access
Overall status
Available
Start date
Not reported
Completion date
Not reported
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

chronic fatigue, chronic fatigue symptoms, fatigue post viral, long covid, post-covid condition, post-covid syndrome, post-covid-19 condition